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ABSTRACT
Background: Inhaled corticosteroid (ICS) has played an important role in the management of asthma. Al-
though several kinds of ICSs are currently available, there is no established strategy for ICS selection.
Methods: Using the data from the 2004 questionnaire surveys by the Niigata Asthma Treatment Study Group,
we analyzed relationships between each patient and the ICS employed on the basis of patient background,
asthma control and treatment, and indicated characteristics of ICS selection by the physician.
Results: Of 2852 cases, 2279 (79.9%) were ICS users, and 1513 (66.4% of ICS users) were classified as be-
ing in the fluticasone propionate (FP) group, 438 (19.2%) in the budesonide (BUD) group, and 240 (10.5%) in
the hydrofluoroalkane-beclometasone (HFA-BDP) group, indicating that FP was a standard ICS in this study.
The mean age was significantly lower in the BUD group (52.3+−18.2 years) and was significantly higher in the
HFA-BDP group (59.9+−17.0 years) than that in the FP group (55.8+−16.6 yaers). The proportion of female
patients was significantly higher not in the HFA-BDP (46.5%) but in the BUD group (59.0%) than in the FP
group (51.1%). These results indicated that BUD was frequently prescribed to young female and HFA-BDP was
employed in the elderly patients irrespective of gender compared with FP.
Conclusions: Our study indicates that ICS selection is reasonably adapted to each patient’s background at
least in the surveyed area. We need to elucidate the characteristics of ICS selection further in the future as new
ICS and devices are developed.
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ABBREVIATIONS
AIA, aspirin intolerant asthma; BUD, budesonide; DPI, dry powder inhaler; FP, fluticasone propionate; HFA-
BDP, hydrofluoroalkane-beclometasone; ICS, inhaled corticosteroid
INTRODUCTION
The management of bronchial asthma has changed
since it has been recognized as a chronic airway in-
flammation.1,2 Guidelines for bronchial asthma in
many countries3-5 recommend inhaled corticosteroids
(ICS) as the main treatment. Therefore, ICS plays an
essential and important role in the management of
bronchial asthma. In the clinical setting, the preva-
lence of ICS has resulted in excellent asthma con-
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The treatment of asthma by ICS involves the seri-
ous problem of ICS selection for individual patients.
Although the efficacy of ICS is one of the most impor-
tant factors for ICS selection, it can be influenced by
various factors, including distribution and metabo-
lism of ICS to bronchi, drug compliance of the pa-
tients, and inhalation proficiency of each ICS device
employed.7 In fact, we previously reported the effect
of ICS compliance on the control of asthma.8 It was
also reported that ICS devices could affect not only
asthma control but also asthma death.9 These factors
indicate that the differences among various ICSs, in-
cluding efficacy, depend on the differences not only
of inhaled medicine itself but also the relationship be-
tween individual patients and the employed ICS. Con-
sidering this characteristic of ICS, physicians must
select the most adequate ICS for each asthmatic pa-
tient. However, there have been few reports focusing
on ICS selection.
In a clinical setting, many patients actually use the
ICS recommended by their physician. Their election
may be based on the efficacy of ICS that can be influ-
enced by factors as mentioned above. Therefore, the
use of ICS in each patient can be related to certain
characteristics for ICS selection. Starting in 1998 a
regular questionnaire survey by the Niigata Asthma
Treatment Study Group was administered; the survey
considered problems concerning asthma manage-
ment. The subjects in this survey were adult patients
with bronchial asthma who visited medical institu-
tions in the Niigata prefecture. The attending physi-
cians of these patients were included in the survey.
On the basis of these surveys, we reported the clini-
cal characteristics of adult bronchial asthma pa-
tients,10 the characteristics of elderly bronchial
asthma11 and near fatal asthma,12 the relationship be-
tween smoking and gender in asthmatics,13 and
changes in asthma management.14,15 These surveys
clearly indicated which ICS was being employed for
asthmatic patients. Using the data from 2004 surveys,
when there were 3 major available ICSs, including
hydrofluoroalkane-beclometasone (HFA-BDP) pres-
surized metered-dose inhaler (pMDI), fluticasone
propionate (FP) dry powder inhaler (DPI), and
budesonide (BUD) DIP in Japan, we analyzed the re-
lationship between individual patients and the em-
ployed ICS focusing on patient background, asthma
control and treatment, and indicated characteristics
of ICS selection in accordance with each asthma pa-
tient by the physician.
METHODS
Each institute in the Niigata prefecture participated in
this study with the intention of joining the Niigata
Asthma Treatment Study Group. This study was per-
formed with the approval of the Ethics Committees at
the School of Medicine of Niigata University in the
Niigata prefecture, Japan, or at each attending institu-
tion under the Ethical Principles for Medical Re-
search Involving Human Subjects, Declaration of Hel-
sinki. The study involved 28 large hospitals (200 beds
or more), 15 small hospitals (less than 200 beds), and
35 clinics (no beds). A total of 3650 questionnaires
were prepared, and 2865 were answered (response
rate, 78.5%). Table 1 presents the contents of the
questionnaire (originally in Japanese). The question-
naire study was performed over 2 months from Sep-
tember to October 2004. Subjects were adult patients
(aged 16 years and more) with bronchial asthma who
regularly visited the participating institutes for
asthma management (typically once or twice per
month). The recruited patients were asked to com-
plete the questionnaire by themselves. Therefore, the
understanding of technical terms such as “attack” or
“unconsciousness” in the questionnaire (Table 1) de-
pended upon the individual patients.
For an evaluation of asthma control, patients were
asked about their mean expiratory peak flow value
and the incidence of asthma attacks during the 2
weeks prior to answering the questionnaire. During
the year prior to the performance of the question-
naire, the patients were also asked to provide infor-
mation about the asthma affecting them by choosing
1 of the following 3 answers: “few attacks,” “seasonal
attacks,” and “frequent attacks.” Furthermore, they
were asked about asthma-related work or school ab-
sences. The questionnaires included questions on
asthma-related symptoms in the 2 weeks prior to the
questionnaire, including those regarding cough and
sputum in the morning and at night, and sleep distur-
bances. The questionnaire also inquired about
asthma-related emergencies, including ambulance
use, emergency department visits, and hospitaliza-
tion, and life-threatening events such as unconscious-
ness during asthma attacks, attacks requiring respira-
tor management, and asthma attacks induced by an
anti-inflammatory agents (aspirin intolerant asthma,
AIA). The subjects were required to answer with a
“yes” or “no” to the following 5 questions: “Have you
ever been hospitalized due to asthma?”; “Have you
ever been taken by ambulance or visited an emer-
gency room due to an attack?”; “Have you ever been
placed on a respirator due to an asthma attack?”;
“Have you ever been unconscious due to an asthma
attack?”; and “Have you ever had an attack induced
by anti-inflammatory drugs including painkillers, anti-
pyretics, or cold medicine?” To evaluate problems in
asthma management and treatment related to normal
activity levels, the questionnaires asked patients
about their satisfaction in daily life. The subjects an-
swered by choosing 1 of 5 answers: “very satisfied”;
“fairly satisfied”; “mediocre”; “slightly dissatisfied”;
and “dissatisfied.”
In addition to monitoring the completion of the
questionnaire by the patients, physicians were asked
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Table 1 Questionnaires administered to asthmatic patients in this study (the original was in Japanese)
Age:　　　years old　　　Gender: male or female
Question 1
When were you first diagnosed as having bronchial asthma?　　Year:　　Month:　　Day:
Question 2
1) Choose your smoking status
 (non-smoker, ex-smoker, curent smoker)
2) To ex-smoker, please answer folowings:
At what age did you start smoking cigarete? Your starting age:
At what age did you stop smoking cigarete? Your stopping age:
How many cigaretes did you smoke per day? Pieces/day (mean):
Is your stopping smoking related to your asthma? Yes or No:
3) To curent smoker, please answer the folowing:
How old did you start cigarete smoking? Your starting age:
How many cigaretes did you smoke per day? Pieces/day (mean):
Question 3
1) Do you use a peak-flow meter?　      Yes or No
2) What was the average value of your peak-flow meter during the last 2 weeks?
         Morning:　　　 Night:
Question 4 Select one answer to each the folowing questions:
1) How often did you have asthma atacks during the last 12 months?
 (frequent atacks, seasonal atacks, few atacks)
2) How often did you have asthma atacks during the last 2 weeks?
 (5―7/week, 3―4/week, 1―2/week, absent)
3) How severe were your asthma atacks during the last 2 weeks?
 (impossible to move, impossible to lie down, possible to lie down, strider, dyspnea on exertion)
4) Have you ever been hospitalized due to asthma?
 (yes, no)
5) Have you ever been taken by ambulance or visited an emergency room due to an atack?
 (yes, no)
6) Have you ever been placed on a respirator due to an asthma atack?
 (yes, no)
7) Have you ever been unconscious due to an asthma atack?
 (yes, no)
8) Have you ever had an atack induced by anti-inflammatory drugs including painkilers, antipyretics, or cold medicine?
9) Have you been absent from work or school due to an asthma atack?
 (yes, no)
Question 5
How bad was your asthma during the last 2 weeks?
 (very good, fairly good, mediocre, slightly bad, bad)
Question 6
Describe your symptoms during the last 2 weeks:
1) in the morning
 (cough, sputa, chest tightness, stridor, dyspnea, no symptoms)
2) at night
 (cough, sputa, chest tightness, stridor, dyspnea, no symptoms)
3) sleep disturbance
 (sometimes cannot fal asleep due to dyspnea, cannot to have a good sleep due to dyspnea, waking up in the night due 
to chest tightness, non)
Question 7
Do you feel satisfied with your daily life?
 (very satisfied, fairly satisfied, mediocre, slightly dissatisfied, dissatisfied)
Ota K et al.
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Table 2 Patient background
HFA-BDPBUDFP
59.9＋/－17.0＊＊＊52.3＋/－18.2＊＊＊55.8＋/－16.6Age (year) 
120/113 (53.5/46.5)174/250 (41.0/59.0)＊＊＊723/755 (48.9/51.1) Gender: male/female (%) 
13.6＋/－13.111.8＋/－12.9＊＊＊14.0＋/－13.1Duration (year) 
162/73 (68.9/31.1)306/115 (72.7/27.3) 1000/466 (68.2/31.8)Type: atopic/nonatopic (%) 
58/64/82/22120/150/142/17＊＊404/408/520/119Severity: Step1/2/3/4 
(25.7/28.3/36.3/9.7)(28.8/35.0/33.1/4.0) (27.8/28.1/35.8/8.2) (%) 
103/102/28200/154/151＊＊＊673/565/220Smoking status: Non/Ex/Cu
(44.2/43.8/12.0)(39.6/30.5/29.9) (46.2/38.8/15.1) (%) 
93/120＊142/219＊＊＊672/628PEF use: use/non-use (%) 
＊: p＜0.05, ＊＊: p＜0.01, ＊＊＊: p＜0.001 v.s. FP, FP: fluticasone dry powder inhaler, BUD: budesonide dry powder inhaler, HFA-BDP: 
hydrofluoroalkane-beclometasone pressurized metered-dose inhaler, Non: non-smoker, Ex: exsmoker, Cu: curent smoker, PEF: peak flow 
meter.
to supply details on current treatment, primarily iden-
tifying control medication, the type of asthma (atopic
or nonatopic) in accordance with the elevation in se-
rum total IgE or detection of specific IgE for aller-
gens, and the severity of asthma in accordance with
the Japanese Society of Allergology guideline for the
diagnosis and management of bronchial asthma. The
definition of severity of asthma is essentially the same
as that used by the Global Initiative for Asthma.
The representative results for continuous variables
were expressed as arithmetic means and standard de-
viations. The differences between groups regarding
continuous variables were evaluated with Kruskal-
Wallis test and Wilcoxon’s rank sum test. Chi-square
test was used to assess the significance of differences
in proportions among groups. In all statistical analy-
ses, a p-value less than 0.05 was considered statisti-
cally significant. All analyses were performed using
SPSS Statistics 17.0 (SPSS, Chicago, IL, USA) soft-
ware.
RESULTS
PATIENT BACKGROUND
Of the patients who completed this questionnaire,
2279 (79.9%) were ICS users, and 1513 (66.4% of ICS
users) were classified as being in the FP group, 438
(19.2% of ICS users) were classified as being in the
BUD group, 240 (10.5% of ICS users) were classified
as being in the HFA-BDP group, and 88 (3.8% of ICS
users) were not classified as being in any of these 3
groups (chlorofluorocarbon beclometasone pressur-
ized metered-dose inhaler [CFC-BDP], 78; the lack of
the used ICS trade-name, 10). Table 2 summarizes
the backgrounds of patients in the FP, BUD, and
HFA-BDP groups. The mean age was significantly
lower in the BUD group and was significantly higher
in the HFA-BDP group than that in the FP group. The
proportion of female patients was significantly higher
not in the HFA-BDP but in the BUD group than in
the FP group. The duration of the disease was signifi-
cantly less in the BUD group than that in the FP
group. The proportion of patients with step 4-disease
severity was significantly lower in the BUD group
than that in the FP group. The proportion of current
smokers was also significantly higher in the BUD
group than that in the FP group. The number of peak-
flow meter (PEF) users was significantly higher in
the BUD and HFA-BDP group than those in the FP
group. There were no significant differences in type
of asthma between the FP and BUD groups. There
were no significant differences in age, disease dura-
tion, type of asthma, disease severity, or smoking
state between the FP and HFA-BDP groups.
DRUGMEDICATION
In terms of medication (Table 3), the used dose of
ICS was significantly greater in the BUD group and
was significantly less in the HFA-BDP group than
that in the FP group. There was a significantly lower
usage of oral corticosteroids and salmeterol (SML)
among patients in the BUD group and a significantly
lower usage of SML among patients in HFA-BDP
group, compared to the FP group. Further, there was
a higher usage of tulobuterol patch (p-TBL) and oral
sustained-released theophylline (OSRT) in the HFA-
BDP group compared to the FP group. The used
doses of oral corticosteroid, calculated as predniso-
lone, in the BUD group were significantly less than
those in the FP group.
ASTHMA CONTROL AND SYMPTOMS
There was a higher rate of asthma attacks during the
2 weeks prior to answering the questionnaire in the
BUD group than that in the FP group. Except for this,
there were no significant differences between the FP
and BUD groups in asthma control and symptoms
during the 2 weeks prior to answering the survey
(Table 4A). During the 1 year period prior to answer-
ing the survey, the proportion of respondents who re-
ported “few” asthma attacks was significantly lower;
further, the proportion of respondents who reported
“seasonal” asthma attacks was significantly higher in
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Table 3 Drug/Medication
HFA-BDPBUDFP
345＋/－202＊＊＊534＋/－274＊＊＊407＋/－206ICS doses (μg/day)
108/132 (45.0/55.0)183/255 (41.8/58.2)707/806 (46.7/53.3)LTRA use: use/non-use (%)
21/219 (8.8/91.3)18/420 (4.1/95.9)＊115/1398 (7.6/92.4)OCS use: use/non-use (%)
6.1＋/－3.84.6＋/－2.4＊6.2＋/－3.6OCS dose (mg/day: calculated as PSL)
34/206 (14.2/85.8)＊＊＊68/370 (15.5/84.5)＊＊＊360/1153 (23.8/76.2)SML use: use/non-use (%)
37/203 (15.4/84.6)＊46/392 (10.5/89.5)153/1360 (10.1/89.9)p-TBL use: use/non-use (%)
154/86 (64.2/35.8)＊＊＊248/190 (56.6/43.4)877/634 (58.3/41.7)OSRT use: use/non-use (%)
＊: p＜ 0.05, ＊＊＊: p＜ 0.001 v.s. FP, FP: fluticasone dry powder inhaler, BUD: budesonide dry powder inhaler, HFA-BDP: 
hydrofluoroalkane-beclometasone pressurized metered-dose inhaler, ICS: inhaled corticosteroid, LTRA: leukotriene receptor antagonist, 
OCS: oral corticosteroid, PSL: predonisolone, SML: salmeterol, p-TBL: tulobuterol patch, OSRT: oral sustained-released theophyline.
Table 4A Incidence of asthma atacks, percentages of predicted peak flow values, asthma-related symptoms and sleep distur-
bances during the two weeks prior to answering the questionnaire
HFA-BDPBUDFP
44/140 (23.9/76.1)112/239 (31.9/68.1)＊314/879 (26.3/73.7) Asthma atacks: present/absent (%) 
365＋/－161383＋/－120394＋/－161PEFV (morning) 
377＋/－140394＋/－122406＋/－221PEFV (night) 
97/143 (40.4/59.6)188/250 (42.9/57.1) 599/914 (39.6/60.4) ARS in morning: present/absent (%) 
60/180 (25.0/75.0)127/311 (29.0/71.0) 396/1117 (26.2/73.8) ARS in night: present/absent (%) 
30/210 (12.5/87.5)62/376 (14.2/85.8) 174/1339 (11.5/88.5) Sleep disturbance: present/absent (%) 
＊: p＜0.05 v.s. FP, FP: fluticasone dry powder inhaler, BUD: budesonide dry powder inhaler, HFA-BDP: hydrofluoroalkane-beclometa-
sone pressurized metered-dose inhaler, PEFV: peak flow value, ARS: asthma-related symptoms.
Table 4B Asthma atacks and asthma-related work absences during the one year period prior to answering the questionnaire
HFA-BDPBUDFP
19/65/12045/149＊＊＊/164＊＊＊163/396/719AA: frequent/seasonal/few
(9.3/31.9/58.8)(12.6/41.6/45.8) (12.8/31.0/56.3) (%) 
15/152 (9.0/91.0)52/310 (14.4/85.6) 153/1045 (12.8/87.2) ARWA: present/absent (%) 
＊＊＊: p＜0.001 v.s. FP, FP: fluticasone dry powder inhaler, BUD: budesonide dry powder inhaler, HFA-BDP: hydrofluoroalkane-beclome-
tasone pressurized metered-dose inhaler, AA: asthma atacks, ARWA: asthma-related work or school absences.
Table 5 Satisfaction in daily life
Very satisfied/ fairly satisfied/ mediocre/ slightly 
dissatisfied/dissatisfied (%)
277/820/216/125/18 (19.0/56.3/14.8/8.6/1.2)FP
72/231/84＊/32/5 (17.0/54.5/19.8/7.5/1.2)BUD 
48/139/31/17/0 (20.4/59.1/13.2/7.2/0.0)HFA-BDP 
＊: p＜ 0.05 v.s. FP, FP: fluticasone dry powder inhaler, BUD: 
budesonide dry powder inhaler, HFA-BDP: hydrofluoroalkane-be-
clometasone pressurized metered-dose inhaler.
the BUD group than that in the FP group, despite no
significant differences in asthma-related work or
school absences (Table 4B). There was no significant
difference in asthma-related work or school absences
between the HFA-BDP and FP groups (Table 4A, B).
SATISFACTION IN DAILY LIFE AND ASTHMA-
RELATED EMERGENCY EPISODES
The proportion of respondents who reported “medio-
cre” for the satisfaction in daily life was significantly
higher in the BUD group than that in the FP group,
despite no significant differences between the FP and
BUD groups (Table 5). There was no significant dif-
ference in satisfaction in daily life between the FP and
HFA-BDP groups (Table 5). Table 6 summarizes the
results regarding asthma-related emergency epi-
sodes. Lower rates of hospitalization, and ambulance
or emergency department visits were reported by pa-
tients in the BUD group compared with those in the
FP group. The rates of asthma attacks with uncon-
sciousness and AIA episodes were also significantly
lower in the BUD than in the PF group. There were
no significant differences between the FP and HFA-
BDP groups except the significantly higher rate of
respirator management history in the HFA-BDP
Ota K et al.
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Table 6 Hospitalization, ambulance use or ED visits, atacks with unconsciousness, respirator management and AIA atacks
HFA-BDPBUDFP
114/103 (52.5/47.5)152/257 (37.5/62.5)＊＊＊687/723 (48.7/51.3)Hospitalization: present/absent (%) 
88/126 (41.1/58.9)140/269 (34.2/65.8)＊＊592/821 (41.9/58.1)Ambulance use or ED visits: present/absent (%) 
15/190 (7.3/92.7)16/380 (4.0/96.0)＊103/1269 (7.5/92.5)Atacks with unconsciousness: present/absent (%) 
22/184 (10.7/89.3)＊19/376 (4.8/95.2)92/1275 (6.7/93.3)Respirator management: present/absent (%) 
17/202 (7.8/92.2)24/378 (6.0/94.0)＊130/1277 (9.2/90.8)AIA atacks: present/absent (%) 
＊: p＜0.05, ＊＊: p＜0.01, ＊＊＊: p＜0.001 v.s. FP, FP: fluticasone dry powder inhaler, BUD: budesonide dry powder inhaler, HFA-BDP: 
hydrofluoroalkane-beclometasone pressurized metered-dose inhaler, ED: emergency department, AIA: aspirin induced asthma.
group.
DISCUSSION
The aim of this study was to compare the various
asthmatic patients classified on the basis of the kind
of employed ICS with their associated clinical fea-
tures, and to find characteristics of ICS selection by
physicians suitable for each asthma patient. As more
than two decades after the introduction of ICS have
passed, the characteristics of ICS selection can be in-
cluded in the data of the questionnaire survey. When
chlorofluorocarbon beclometasone was available,
there were no problems of ICS selection in accor-
dance with the patient characteristics because there
were no other ICSs with little systemic adverse ef-
fects due to corticosteroids. Later, new ICSs, includ-
ing their improved pharmacological properties and
progressive devices, have become available. In Japan,
FP, BUD, and HFA-BDP were offered in 1998, 2001,
and 2003, respectively. Further, the questionnaire
survey employed in this study was performed 6, 3,
and 1 years following FP, BUD, and HFA-BDP intro-
duction, respectively. It is very clear that FP played a
major role in the ICS asthma treatment, indicating
that FP is the standard ICS in Japan. However, con-
sidering the background of ICS introduction men-
tioned above, the earlier recognition of FP than BUD
and HFA-BDP had a certain influence on the FP ma-
jority. In other words, the already accepted percep-
tion of FP as a major second generation ICS by the
physicians might be advantageous to its use.
For the prescription of ICSs to asthmatic patients, a
comparison of BUD and HFA-BDP with FP will be
the first step in the selection of ICS by each physi-
cian, and the accumulation of this step would reflect a
certain characteristic of ICS selection in our data
from the questionnaire survey. Therefore, in this
study, we compared BUD and HFA-BDP group with
FP group. Table 2 clearly showed that there were ap-
parent differences in age, gender, and disease dura-
tion between FP and BUD, or FP and HFA-BDP. Re-
garding for BUD group, it was used in younger age
patients and predominantly in female. These results
indicate that both age and gender were considered in
the selection of BUD. Recently, the safety of ICS dur-
ing pregnancy was established,16 and BUD was rec-
ognized as a safe ICS option for the first time.17 This
was likely reflected in our results. In other words,
physicians can safely opt for BUD in potentially preg-
nant patients. Other characteristics in the BUD group
were found in disease severity and ICS dose. Except
for asthma attacks during the 2 weeks prior to an-
swering the questionnaire, there were no differences
in the indicators of asthma control in this study be-
tween FP and BUD groups (Table 4). However,
milder patients tended to employ BUD than FP (Ta-
ble 2) and the users of BUD less frequently employed
SML than FP. Although the doses of BUD were
greater than those of FP, it was less than double the
amount of FP. It was reported that the clinical efficacy
of BUD was approximately equal to half of that of
FP.18 Furthermore, the Ministry of Health, Labour
and Welfare in Japan have decided that the allowable
maximum dose of BUD is 2 times that of FP and
HFA-BDP. Therefore, the actual doses of ICS in the
BUD group could be considered to be less than those
in the P group, indicating that the physicians tended
to select BUD for somewhat mild asthmatic patients.
Lower rates of hospitalization, ambulance, or emer-
gency department visits in the BUD group was likely
to be related with this BUD property. However, this
BUD feature might be uncertain, because the com-
parison among dose efficacy responses of each ICS
has not been completely established yet. The causes
of the low rates of asthma attacks with unconscious-
ness and AIA episodes in the BUD group remain un-
known.
HFA-BDP was employed in older patients without
gender differences, compared to FP (Table 2). In Ja-
pan, FP was used almost like a DPI. Although DPI re-
moves the need for inhalation-actuation synchrony, it
usually requires a certain inspiratory flow rate. It was
reported to be difficult for patients with impaired lung
function, including low forced expiratory volume 1
second and vital capacity, to adequately inhale FP
powder.19 Moreover, there is a problem in loading
and priming for DPI use, and medical personnel are
required to possess knowledge on accurate usage of
DPI.20 In cases of the elderly, the same situation as
mentioned above can be frequently anticipated. In
contrast, the use of pMDI, including HFA-BDP, does
not require either adequate inspiratory flow rate or
Selection of Inhaled Corticosteroid
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correct loadingpriming for DPI use, although the
handling pMDI requires inhalation-actuation syn-
chrony. These factors might be the causes of high us-
age rates of HFA-BDP in elderly patients. The pa-
tients in HFA-BDP were older and employed PEF to a
lesser extent than those in FP; which corresponded
with the results of our previous report.11 The reasons
for the lower doses of ICS, the lower usage rate of
SML, the higher usage rate of OSRT, and the higher
usage rate of p-TBL in the HFA-BDP group than
those in FP group also might be related to the fact
that the patient age in HFA-BDP group was greater
than that in FP group. The causes of the high rate of
respirator management in the HFA-BDP group are
still unknown, as in the case of the BUD group. On
the basis of the data on HFA-BDP selection by physi-
cians, HFA-BDP can be considered to be suitable for
elderly patients with asthma.
In summary, we attempted to elucidate characteris-
tics of the ICS selection in each patient by compari-
son with the characteristics of each ICS user in the
data obtained from questionnaire surveys. FP was
likely to be a standard ICS in Japan. BUD was pre-
scribed to young and female patients; it is affected by
both age and gender. HFA-BDP was used in the eld-
erly patients irrespective of gender. As we retrospec-
tively showed characteristics of ICS selection, this
was a limitation in our study, and more prospective
studies will be required. In the future, new ICSs and
devices will be developed, and the principles of ICS
selection will also be altered. However, we should try
to elucidate the characteristic of ICS selection
adapted to the circumstance of ICS development and
apply them in clinical settings.
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